Pharsight™ Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight’s approach enhances the fundamental element of success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is the world leader in analysis and simulation of PK/PD data, providing industry standard software for PK/PD modeling and noncompartmental analysis. WinNonlin generates all figures, tables, and listings you need for PK/PD studies.

Financials

Date Type Amount Investors Valuation
09/02/02 Series B 7.5M Samson Venture Partners, Iris Ventures, Venture Capital Fund of New England, CEI Ventures, Litle & Company, MerchantBanc Venture Partners, Citizens Bank, Inquire, Ziegler Meditech Equity Partners, rts Alliance Unknown

People

Cynthia Stephens (SVP/CFO)

William Gillespie (VP Drug Development)

Mona Sowiski (SVP Strategic Consulting Services)

Jamrs Hayden (SVP Sales)

View more details about all 27 people at Pharsight